Blood Plasma Derivatives Companies

CSL Ltd. Inaugurated their USD 900 million plasma fractionation facility in Australia, significantly expanding their global production capacity and market reach. Partnered with research institutions to explore next-generation plasma-derived therapies and personalized treatment options.

Grifols, S.A. Completed the acquisition of Tiancheng (Germany) Pharmaceutical Holdings AG, a leading plasma protein manufacturer, strengthening their European presence and access to raw materials. Focused on expanding their portfolio of plasma-derived immunoglobulins and albumin products to cater to diverse patient needs.

Takeda Pharmaceutical Company Limited Announced plans to invest USD 300 million in the construction of a new plasma derivatives production facility and warehouse in Belgium, indicating their commitment to long-term market growth. Collaborated with patient advocacy groups to raise awareness about plasma-derived therapies and improve access for individuals with rare diseases.

Octapharma AG Received FDA approval for their Gamifant® (immune globulin intravenous, human [Grifols]) for the treatment of primary immunodeficiency diseases (PIDDs), offering a new option for patients with specific antibody deficiencies. Emphasized their dedication to delivering high-quality and affordable plasma-derived products to patients worldwide.

Baxter International Partnered with a leading plasma fractionation company to expand their access to plasma and ensure continued supply of their critical plasma-derived therapies. Focused on developing innovative delivery systems and dosage forms for plasma-derived medications to improve patient convenience and treatment compliance.

• Grigols (Spain)


• SK Plasma Co. Ltd. (South Korea)


• Bain Capital LLC (US)


• Biotest AG (Germany)


• Baxter International Inc. (US)


• Octapharma AG (Switzerland)


• CSL Limited (Australia)


• Kedrion S.p.A (Italy)


• Fusion Healthcare (India)